Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.60%17 Buyback Yield % is -19.44 as of Aug. 14, 2026. GuruFocus rates ROCO:7762 with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 271 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 85.61% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Pet Pharm Biotech Co Buyback Yield % Related Terms
Pet Pharm Biotech Co Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a Buyback Yield % of -19.44 as of Aug. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pet Pharm Biotech Co and its competitors. According to the industry distribution chart, Pet Pharm Biotech Co ranks #232 out of 271 companies in the Drug Manufacturers industry, placing it in the top 85.6%.
Is Pet Pharm Biotech Co's Buyback Yield % too high?
Pet Pharm Biotech Co's current Buyback Yield % is -19.44. Based on the distribution chart, Pet Pharm Biotech Co ranks #232 out of 271 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #232 out of 271 companies for Buyback Yield %. This places Pet Pharm Biotech Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Buyback Yield % is -19.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Buyback Yield % of -19.44. The current Buyback Yield % is -19.44. Pet Pharm Biotech Co's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Buyback Yield % is -19.44 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
17GF Score
Get the complete analysis for ROCO:7762
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
